SCHEMBL4673744

SCHEMBL4673744

O=C(C=C(O)c1nn[nH]n1)c1cnn(Cc2ccncc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 5/20 0.38
MAP4K4 O95819 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
LMNA P02545 2/20 0.34
RIPK1 Q13546 1/20 0.34
TSHR P16473 1/20 0.34
ERCC5 P28715 1/20 0.34
POLB P06746 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
SCD O00767 1/20 0.34
SCD5 Q86SK9 1/20 0.34
S1PR1 P21453 1/20 0.34
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
IKBKE Q14164 1/20 0.32
TBK1 Q9UHD2 1/20 0.32
CES1 P23141 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674490 0.91 KLKB1 (0.43) KLKB1HSD17B10RIPK1ERCC5POLB
SCHEMBL4676019 0.89 KLKB1 (0.40) KLKB1HSD17B10LMNARIPK1KDM4E
SCHEMBL4676023 0.88 KLKB1 (0.42) KLKB1HSD17B10POLBALDH1A1
SCHEMBL4671607 0.88 LMNA (0.43) KLKB1HSD17B10LMNAALDH1A1
SCHEMBL4674633 0.88 HSD17B10 (0.40) KLKB1HSD17B10LMNAKDM4EALDH1A1
SCHEMBL4674679 0.86 L3MBTL1 (0.44) KLKB1HSD17B10ERCC5L3MBTL1
SCHEMBL4672090 0.83 KLKB1 (0.38) KLKB1HSD17B10CYP3A4CYP2C9LMNA
SCHEMBL4672655 0.83 KLKB1 (0.43) KLKB1POLBTDP1L3MBTL1SCD
SCHEMBL4672787 0.82 CREBBP (0.41) TSHRERCC5L3MBTL1KDM4EALDH1A1
SCHEMBL4676260 0.82 MAP4K4 (0.34) KLKB1MAP4K4CYP3A4LMNAERCC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KLKB1 3843/4885MAP4K4 2369/4885HSD17B10 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.